Foresight Biosciences provides technology for glycobiology research with an emphasis on creating tools and in vitro technologies to advance protein-based drug development. Most FDA-approved protein glycoconjugates have very specific structures that affect their function and distribution. Therapeutic proteins derived from non-human cells often exhibit improper glycosylation that require modification prior to administration. Foresight Biosciences has developed technology to facilitate protein posttranslational modification, glycoconjugation and glycan analysis. The company offers benchtop assays for glycoprotein terminal fingerprint analysis, enzymes and convenient kits for identifying, repairing, and modifying protein glycosylation.